New drug doses tested for rare blood cancer

NCT ID NCT05978739

Completed Disease control Sponsor: InnoCare Pharma Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tested two different daily doses of the drug orelabrutinib in 40 people with mantle cell lymphoma, a rare blood cancer. The goal was to see which dose works better at shrinking tumors and controlling the disease. Participants included both newly diagnosed and relapsed patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Orelabrutinib
What this could lead to: If successful, this could help determine the best dose of orelabrutinib to control mantle cell lymphoma with fewer side effects.
What could go wrong: This is a small, early-phase trial with only 40 participants. Results may not apply to all patients, and the drug may not work as well as hoped or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Locations

Chenzhou First People's Hospital

Chenzhou, Hunan, 423003, China
Chongqing Cancer Hospital

Chongqing, Chongqing Municipality, 400030, China
Henan Cancer Hospital

Zhengzhou, Henan, 450003, China
Hubei Cancer Hospital

Wuhan, Hubei, 430079, China
Hunan Cancer Hospital

Changsha, Hunan, 410031, China
Jiangxi Cancer Hospital

Nanchang, Jiangxi, 330029, China
Nanyang Second General Hospital

Nanyang, Henan, 473009, China
Peking University Third Hospital

Beijing, Beijing Municipality, 100191, China
Shanxi Provincial Cancer Hospital

Taiyuan, Shanxi, 030013, China
Sun Yat-sen University Cancer Center

Guangdong, Guangzhou, 510055, China
The Affiliated Cancer Hospital of Xinjiang Medical University

Ürümqi, Uygur Autonomous Region, 830000, China
The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, 230022, China
The First Affiliated Hospital of Bengbu Medical College

Bengbu, Anhui, 233040, China
The First Affiliated Hospital of China Medical University

Shenyang, Liaoning, 110001, China
The First Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310003, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450052, China
The Second Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, 330006, China
The Second Affiliated Hospital of Xi'an Jiaotong University

Xi’an, Shanxi, 710004, China
The Second Hospital of Dalian Medical University

Dalian, Liaoning, 116023, China
Union Hospital Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.